Topical and systemic administration of tranexamic acid on pediatric cardiac surgery
Phase 3
- Conditions
- congenital heart disease.Congenital malformation of heart, unspecifiedQ24.9
- Registration Number
- IRCT20170316033099N11
- Lead Sponsor
- Birjand University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Congenital heart disease
Age between one month and 15 years
Elective cardiac surgery
Surgery performed by one single surgeon
Informed consent form signed by the patient's guardian
Exclusion Criteria
Treatment with anti-coagulants
Presence of hepatic, renal, or respiratory dysfunction
Low cardiac output
Need for re-surgery
Postoperative septicemia
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bleeding volume. Timepoint: From the completion of the surgery up to 48 hours after surgery. Method of measurement: Measurement of chest drainage volume in the chest tube.;Need for blood products including packed red blood cells, fresh frozen plasma, and platelets. Timepoint: From the completion of the surgery up to 48 hours after surgery. Method of measurement: Measurement of the packs in terms of cc.
- Secondary Outcome Measures
Name Time Method